FindTrial
Sign In

Application of new technology of radiotherapy based on TOMO technology for the implementation of whole brain radiotherapy and simultaneous brain metastases and the protection of hippocampus in key functional areas

Application of new technology of radiotherapy based on TOMO technology for the implementation of whole brain radiotherapy and simultaneous brain metastases and the protection of hippocampus in key functional areas

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027539
Enrollment
Unknown
Registered
2019-11-17
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer brain metastases

Interventions

Experimental group versus Control group:Cumulative radiotherapy

Sponsors

Liaoning Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The number of brain metastases =80 points; 4. No important organ failure.

Exclusion criteria

Exclusion criteria: 1. When the vital organs such as heart, liver and kidney are seriously damaged; 2. Those with severe systemic infection, sepsis or concentrated toxemia are not controlled; 3. Hemoglobin <80g/L or white blood cells <3.0*10^9/ before treatment L; 4. Advanced cancer with anemia, weight loss or in a cachexia state.

Design outcomes

Primary

MeasureTime frame
OS;—

Secondary

MeasureTime frame
PFS;ORR;DCR;—

Countries

China

Contacts

Public ContactYingqiu Song

Liaoning Cancer Hospital

1018501023@qq.com+86 18900917411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026